Incyte’s share price soars, driven by strong Q2 2025 results, Niktimvo’s impressive sales, and raised guidance for Jakafi. Find out why INCY stock is a buy.
Incyte: Wall Street Underestimates Strength Of Ruxolitinib Portfolio
view original post
Incyte’s share price soars, driven by strong Q2 2025 results, Niktimvo’s impressive sales, and raised guidance for Jakafi. Find out why INCY stock is a buy.